ZURICH, Jan 23 (Reuters) - Actelion's Opsumit drug
missed a primary endpoint in a late-stage study of patients with
pulmonary arterial hypertension due to Eisenmenger Syndrome, a
doctor involved in the trial said in a statement from the Swiss
drugmaker.
Read more
No comments:
Post a Comment